Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer

RegenXBio (RGNX) announced positive interim Phase 1/2 AFFINITY DUCHENNE trial data for RGX-202, its gene therapy for Duchenne muscular dystrophy, showing a 4.5-point improvement from baseline and a 6.8-point gain over natural history on the NSAA scale at 12 months in treated patients. The company anticipates submitting a BLA in mid-2026, targeting a 2027 commercial launch, while competitor Sarepta Therapeutics recently reported a patient death related to its Duchenne gene therapy, leading to a clinical hold in the EU; RGNX shares are down 11.2% following the announcement.

Analysis

RegenXBio (RGNX) has released positive interim data from its Phase 1/2 AFFINITY DUCHENNE trial for RGX-202, an investigational gene therapy for Duchenne muscular dystrophy. Notably, patients at dose level 2 demonstrated a 4.5-point improvement on the North Star Ambulatory Assessment (NSAA) from baseline and a 6.8-point gain compared to natural history at the 12-month follow-up, with consistent benefits observed across timed function tests. These results, from a cohort of five patients (four reaching 12 months), underpin RegenXBio's strategy to target a Biologics License Application (BLA) submission in mid-2026 and a commercial launch in 2027, with topline data anticipated in the first half of 2026. This encouraging update for RGNX contrasts sharply with recent negative developments for competitor Sarepta Therapeutics (SRPT), which reported a patient death associated with its Duchenne gene therapy, Elevidys, leading to a clinical hold in the EU. Despite the positive RGX-202 data, RGNX stock declined 11.2%, a movement potentially influenced by the small trial size, the extended commercialization timeline, or broader investor apprehension stemming from Sarepta's challenges which contribute to a mixed and cautious overall market sentiment for gene therapies in this indication.

Key Decisions for Investors

• Investors should critically await the H1 2026 topline data for RGX-202 to validate these early positive signals in a larger patient set.
• Closely monitor the ongoing regulatory scrutiny and safety profile of Sarepta's Elevidys, as this will significantly shape the competitive and regulatory environment for Duchenne gene therapies.
• Consider the recent 11.2% RGNX share price drop as a potential inflection point, weighing the promising but early-stage RGX-202 data against heightened sector risks and the 2027 commercialization target.